Pharmacovigilance (PV) inspections are critical checkpoints in ensuring the safety of medicines and the integrity of post-marketing surveillance systems. Conducted by regulatory authorities and national competent authorities, these inspections evaluate whether a Marketing Authorisation Holder (MAH) or its service provider complies with Good Pharmacovigilance Practices (GVP).
1. Understanding the Purpose and Scope of PV Inspections
Pharmacovigilance inspections aim to verify that an organisation has an effective system for the collection, assessment, and reporting of safety information throughout a product’s life cycle.
Authorities conduct two main types of inspections:
- Routine inspections – Scheduled periodically to ensure general compliance.
- For-cause inspections – Triggered by specific concerns, signals, or compliance history.
The scope typically includes reviewing the Pharmacovigilance System Master File (PSMF), Qualified Person for Pharmacovigilance (QPPV) oversight, Individual Case Safety Reports (ICSRs), Signal management, Risk management plans (RMPs), and Vendor oversight.
2. Roles and Responsibilities in Inspection Readiness
The QPPV
The Qualified Person for Pharmacovigilance holds overall accountability for the PV system. Their responsibilities include ensuring the system’s compliance, oversight of safety data, maintaining the PSMF, and acting as a 24/7 point of contact for regulatory authorities.
Pharmacovigilance Team
The PV team supports the QPPV in daily safety operations, processing adverse events, performing signal detection, managing risk minimisation activities, and maintaining quality documentation. Every member must be adequately trained and aware of their role in inspection readiness.
Quality Assurance (QA) Department
QA ensures the PV system operates within the defined quality framework. It conducts internal audits, verifies CAPA implementation, and ensures SOPs are up to date and aligned with GVP requirements.
Regulatory Affairs & IT Support
Regulatory teams coordinate communication with authorities, while IT supports validated electronic systems, data integrity, and secure documentation management, all of which are critical inspection areas.
3.Preparing for a Pharmacovigilance Inspection
Preparation should begin long before receiving an inspection notice. Below are key steps for ensuring your system always remains inspection ready.
A. Maintain a PSMF
The Pharmacovigilance System Master File must accurately describe the PV system, including processes, organisational structure, outsourcing arrangements, and product scope. It should be regularly updated and readily accessible to the QPPV and inspectors.
B. Keep SOPs Updated and Implemented
Standard Operating Procedures (SOPs) form the backbone of compliance. They should be version-controlled, reflect actual practice, and demonstrate adherence to regulatory timelines for safety reporting, signal management, and RMP activities.
C. Ensure Comprehensive Training
All personnel involved in PV (internal or external) must have role-specific training with documented records. Conduct refresher sessions regularly and include mock inspection exercises to reinforce awareness.
D. Conduct Internal Audits and Mock Inspections
Routine internal audits help identify compliance gaps before inspectors do. Mock inspections simulate real scenarios, helping staff gain confidence and ensuring documentation and responses are well-prepared.
E. Strengthen Vendor Oversight
Outsourced PV activities must be managed under formal Safety Data Exchange Agreements (SDEAs) and service contracts. Oversight should include periodic audits, performance metrics, and documentation of corrective actions where needed.
F. Data Integrity and System Validation
Inspectors often assess the validation status of PV databases. Ensure systems have audit trails, restricted access, and backup procedures in place, with validation reports available on request.
4. During the Inspection: Best Practices
When the inspection begins, clarity, organisation, and transparency are the best practices.
5. Post-Inspection Actions
After the inspection, authorities will issue an inspection report highlighting critical, major, or minor findings. The organisation must then:
- Review findings carefully and perform a root cause analysis.
- Develop a Corrective and Preventive Action (CAPA) plan with defined responsibilities and timelines.
- Submit a formal response to the authority within the specified timeframe.
- Verify CAPA effectiveness through follow-up audits or quality checks.
6. Sustaining Inspection Readiness
Inspection readiness is an ongoing process, not an event. Organisations should:
- Integrate inspection preparedness into their Quality Management System (QMS).
- Maintain continuous updates to the PSMF, SOPs, and training programs.
- Track compliance metrics such as ICSR timelines, CAPA closure rates, and signal management KPIs.
- Encourage a culture of proactive compliance where every employee understands the importance of pharmacovigilance.
Key Takeaways
- Be proactive: Inspection readiness should be continuous, not reactive.
- QPPV: Ensure they have oversight and resources to maintain compliance.
- All documentation is inspection-ready: PSMF, SOPs, training, and vendor records should always be current.
- Inspections simulation: Conduct regular mock audits to build confidence and identify weaknesses.
- Act on findings: Use CAPAs and lessons learned to continuously improve the PV system.
Authored By : Lamees El-Heeny
BPharm-Head of Pharmacovigilance, Baupharma.
